ClinicalTrials.gg
CompletedNCT03877562Updated Apr 28, 2020

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

A Phase 1 interventional study of Olanzapine and CORT118335 in Antipsychotic-induced Weight Gain, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Weight Gain with a site in United Kingdom — 3 open to participants now, 3 under way, 1 of them phase 3. Weight Gain · United Kingdom.

Started
2019
with 1 other
Phase 1
Only one
of the 11
Registered
4th of 11
by date
Lead sponsor
1 of 11
Corcept Therapeutics

Among the 11 studies in Weight Gain with a site in United Kingdom, this one is one of 2 that started in 2019, is the only one in phase 1, and was the 4th registered.

Weight Gain

318 studies on the registry are indexed under Weight Gain; 48 are open to participants now.

Browse Weight Gain studies →

Open to participants now

3 of the 11 studies in Weight Gain with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 31 Weight Gain studies recruiting now, 8 (26%) set no upper age limit and 23 (74%) stop at 75 or younger; 6 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Weight Gain with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine which looks like CORT118335 but contains no active medicine). Safety and tolerability of CORT118335 when taken with olanzapine will also be evaluated.

03

Conditions studied

  • Antipsychotic-induced Weight Gain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18.0 to 25.0 kg/m\^2, inclusive
  • Stable body weight as indicated by assessment at screening and pre-dose
  • Able to swallow the size and number of tablets required
  • Provide written and agree to adhere to study restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  • Have received any medicine in a clinical research study within the previous 3 months, or CORT118335 at any time
  • Employee, or immediate family member of a study site or Sponsor employee
  • Have a pregnant partner
  • History of abuse of any drug or alcohol, or regularly consume more than 21 units alcohol/week
  • Smokers or users of e-cigarettes and nicotine replacement products within the last 6 months
  • abnormal results of clinical laboratory safety tests, , or measurement of heart rate and blood pressure
  • History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, or gastrointestinal disease, neurological or psychiatric disorder
  • History of jaundice or gallstones or had a cholecystectomy
  • Family history or known risk for narrow angle glaucoma
  • Consumed liquorice or other glycyrrhetic acid derivatives regularly in the past 6 months
  • Any condition that could be aggravated by and/or mineralocorticoid antagonism (e.g., asthma, any chronic inflammatory condition, postural hypotension/orthostatic symptoms)
  • Presence or history of clinically significant allergy
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Are taking, or have taken, any prescribed or over-the-counter drug within 14 days other than paracetamol or standard dose multivitamins. Longer restrictions apply for some medicines.
  • Lactose intolerance.

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Olanzapine plus CORT118335

    Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.

    Drug: Olanzapine · Drug: CORT118335

  • Placebo comparator
    Olanzapine plus Placebo

    Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.

    Drug: Olanzapine · Drug: Placebo

Interventions

  • Olanzapine 10 mg oral tablet

  • CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets

  • DrugPlacebo

    Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in Body Weight

    Time frame: Pre-dose on Day 1 (Baseline) and Day 15

Secondary outcomes

  1. Percentage of Participants with One or More Adverse Events

    Time frame: Up to Day 28

  2. Percentage of Participants with One or More Serious Adverse Events

    Time frame: Up to Day 28

  3. Percentage of Participants Discontinued from the Study due to an Adverse Event

    Time frame: Up to Day 28

  4. Mean Change from Baseline in Glucose

    Time frame: Pre-dose on Day 1 (Baseline), pre-dose on Days 8, 15, and 28

  5. Mean Change from Baseline in Insulin

    Time frame: Pre-dose on Day 1 (Baseline), pre-dose on Days 8, 15, and 28

  6. Mean Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Time frame: Pre-dose on Day 1 (Baseline), pre-dose on Days 8, 15, and 28

  7. Mean Change from Baseline in Triglycerides

    Time frame: Pre-dose on Day 1 (Baseline), pre-dose on Days 8, 15, and 28

  8. Mean Change from Baseline in Waist-to-Hip Ratio

    Time frame: Pre-dose on Day 1 (Baseline), Days 8, 15, and 28

  9. Plasma Pharmacokinetics (PK) of CORT118335: Time from Dosing at which Maximum Concentration is Apparent (tmax)

    Time frame: Pre-dose and at pre-specified time points up to 24 hours after dosing on Day 7

  10. Plasma PK of CORT118335: Maximum Observed Concentration (Cmax)

    Time frame: Pre-dose and at pre-specified time points up to 24 hours after dosing on Day 7

  11. Plasma PK of CORT118335: Area Under the Concentration-Time Curve Over the Dose Interval (AUCtau)

    Time frame: Pre-dose and at pre-specified time points up to 24 hours after dosing on Day 7

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Mar 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2019
First posted
Mar 15, 2019
StartActual
Apr 1, 2019
Primary completionActual
Mar 13, 2020
CompletionActual
Mar 25, 2020
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03877562
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Apr 1, 2019
Primary completion
Mar 13, 2020
Completion
Mar 25, 2020
Last update
Apr 28, 2020

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion